☰

MeTaPharmaceutical

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of MeTaPharmaceutical's published strategy and is not endorsed by, or produced in cooperation with, MeTaPharmaceutical. Company website

Strategic priorities

MeTaPharmaceutical operates across 4 stated priorities, with the most concrete near-term plan anchored on clinical-stage transformation.

Transition from raw material supplier to clinical-stage pharmaceutical company through the MP-5342 immunometabolism platform targeting IBD, MS, and PBC indications by H2 2026.

Synchronize the complete value chain from raw material sourcing (including contracted primrose farmers) through manufacturing to pharmacy distribution, creating a closed-loop "Demand-to-Discovery" system.

Unify operations across Sejny (raw materials), Plock (industrial manufacturing), Kutno (distribution), and Sleza (supplements/corporate) under the rebranded MeTa Pharmaceutical identity.

Challenges we see

  • Digital Integration

    Multi-Site Data Fragmentation

    The rapid acquisition spree (BeQ Lab 2021, Plock 2022, CEFEA 2023) and 2024 rebranding created a geographically dispersed operation across four Polish sites, each with potentially different IT/OT systems, data formats, and operational protocols.

    Without a unified digital thread, quality inconsistencies and delayed decision-making arise, and batch genealogy is hard to demonstrate across the consolidated group.

  • Compliance Regulatory

    Clinical Trial Data Readiness

    The nomination of MP-5342 as their first clinical candidate requires BeQ Lab to meet international IND-enabling study standards and prepare submissions to URPL or EMA by H2 2026.

    Current R&D data management may not meet global clinical data standards, risking gaps in regulatory filings and lost partnership opportunities.

  • Operations Manufacturing

    Micropellet Production Precision

    The flagship Q Maslan Sodu product relies on innovative micropellet technology requiring high-precision granulation and coating processes to ensure consistent absorption characteristics.

    Manual quality control and legacy process monitoring may lead to batch variability, rejected batches, or suboptimal utilization of expensive production equipment.

  • Operations Regulatory

    Supply Chain Traceability

    The pharmacy compounding market requires strict GDP compliance and full traceability from raw material suppliers (including contracted evening primrose farmers) to final pharmacy delivery.

    Current paper-based or fragmented tracking systems create compliance gaps and an inability to rapidly respond to quality incidents across the distribution network.

  • Operations Manufacturing

    Environmental Control Across Remote Sites

    Pharmaceutical manufacturing requires continuous monitoring of temperature, humidity, and pressure to meet GMP standards, particularly challenging for the Sejny greenfield facility in a less industrialized region.

    Environmental excursions at remote sites may go undetected, risking batch failures and regulatory citations during GIF inspections.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Unified Manufacturing Visibility

    The group lacks real-time operational visibility across its four manufacturing and distribution sites, making it impossible to track batch consistency, optimize equipment utilization, or respond proactively to production deviations.

    Implement a centralized MES platform that provides the Board with unified operational dashboards, enabling data-driven decisions and supporting the "synergy effect" central to the MeTa mission.

  2. Lab 4.0 for Clinical Readiness

    BeQ Lab processes complex immunometabolism research data but lacks the integrated LIMS/ELN infrastructure required for IND-enabling studies and eventual clinical trial data submissions to regulatory authorities.

    Deploy a comprehensive Lab 4.0 ecosystem with LIMS, ELN, and bio-informatics capabilities that captures every step of MP-5342 development while ensuring data integrity for regulatory submissions.

  3. Micropellet Quality Assurance

    The Q Maslan Sodu micropellet production process requires precise control of granulation and coating parameters, but current quality control relies on manual sampling and retrospective analysis.

    Implement IIoT sensors and AI-driven quality control to monitor granulation in real-time, predict coating thickness variations, and automatically adjust parameters to maintain batch consistency.

  4. GDP-Compliant Digital Supply Chain

    The distribution arm in Kutno manages temperature-sensitive raw materials for pharmacy compounding but lacks digital tracking systems for cold chain monitoring and provenance verification.

    Implement blockchain-based track-and-trace systems with IoT temperature monitoring to ensure Falsified Medicines Directive compliance and provide real-time visibility from supplier to pharmacy.

  5. Predictive Environmental Monitoring

    The Sejny greenfield facility in a less industrialized region faces challenges maintaining GMP-compliant environmental conditions with limited local technical support for HVAC and critical utility systems.

    Deploy integrated BMS with predictive maintenance capabilities to prevent environmental excursions and enable remote expert support for the Sejny facility.

What we'd propose

  • Digital CDMO

    Unified Manufacturing Execution Platform

    Deploy a centralized MES architecture that connects the Sejny, Plock, and Sleza manufacturing sites to provide real-time production visibility, digital batch records, and OEE tracking for the micropellet production lines.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    BeQ Lab 4.0 Digital Research Platform

    Implement an integrated LIMS/ELN ecosystem for BeQ Lab that captures immunometabolism research data with full traceability, supporting MP-5342 IND-enabling studies and future clinical trial submissions.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Intelligent Micropellet Quality System

    Deploy IIoT-enabled quality monitoring for the Q Maslan Sodu micropellet production process, using computer vision and sensor integration to ensure real-time coating uniformity and granulation precision.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Digital Supply Chain & GDP Compliance Platform

    Implement a comprehensive track-and-trace system for the Kutno distribution center with cold chain IoT monitoring and blockchain-based provenance verification to ensure FMD and GDP compliance.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Integrated Environmental Monitoring & Predictive Maintenance

    Deploy a converged BMS and predictive maintenance platform for the Sejny and Plock facilities, integrating HVAC, utilities, and production equipment monitoring with AI-driven failure prediction.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what MeTaPharmaceutical's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Manufacturing Digitalization 35 → 80
Recent acquisitions likely operate with legacy systems; ISO 22000 certification indicates quality focus but limited Industry 4.0 adoption evidenced by manual processes described.
Lab Informatization 40 → 90
BeQ Lab university spin-off has R&D capability but lacks integrated LIMS/ELN infrastructure required for clinical-stage operations; translational data processing suggests some digital maturity.
IT/OT Convergence 25 → 75
Four geographically dispersed sites acquired over 4 years suggest fragmented OT infrastructure; unified corporate IT likely exists but not integrated with shop-floor systems.
Supply Chain Digitalization 30 → 70
GDP certification demonstrates compliance focus but distribution operations likely rely on traditional tracking; contracted farmer network needs digital integration.
Data Analytics Capability 35 → 85
Research focus on immunometabolism indicates analytical capability but manufacturing and quality data likely siloed; "Demand-to-Discovery" vision requires unified analytics platform.
Environmental & Sustainability 40 → 75
Regional development focus and farmer partnerships suggest ESG awareness; greenfield Sejny facility offers opportunity for sustainable manufacturing design but needs digital monitoring.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with MeTaPharmaceutical, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].